Acadia Pharmaceuticals
ACAD
160 hedge funds and large institutions have $2.16B invested in Acadia Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 62 increasing their positions, 56 reducing their positions, and 25 closing their positions.
1,265% more call options, than puts
Call options by funds: $297M | Put options by funds: $21.8M
11% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 56
2% less capital invested
Capital invested by funds: $2.21B → $2.16B (-$47.4M)
5% less funds holding
Funds holding: 168 → 160 (-8)
28% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 25
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$66.4M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$30.2M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$24.2M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$18.4M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$15M |
| 2 |
HM
HealthCor Management
New York
|
-$10.1M |
| 3 |
TCP
Tourbillon Capital Partners
New York
|
-$8.52M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$8.29M |
| 5 |
HH
HWG Holdings
Houston,
Texas
|
-$7.59M |
ACAD Hedge Fund Activity: Q2 2014 in Review
160 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q2 2014, worth a combined $2.16B — down 2.1% from $2.21B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ACAD and 18 opened new positions — a net loss of 7 holders — while 56 trimmed existing stakes and 62 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $66.4M. The largest seller was Invesco, cutting an estimated $15M.
- 160 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q2 2014, down from 168 in Q1 2014.
- Funds reported $2.16B of Acadia Pharmaceuticals stock for Q2 2014, down 2.1% quarter-over-quarter.
- 18 funds opened new Acadia Pharmaceuticals positions in Q2 2014 and 25 closed out, a net change of -7 holders.
- The largest Acadia Pharmaceuticals buyer in Q2 2014 was T. Rowe Price Associates, an estimated $66.4M added.
- The largest Acadia Pharmaceuticals seller in Q2 2014 was Invesco, an estimated $15M sold.
Based on aggregated 13F filings for Q2 2014.